{
    "doc_id": "mmlu_224_deepseek-ai_DeepSeek-V3",
    "metadata": {
        "model_id": "deepseek-ai/DeepSeek-V3",
        "subject": "nutrition",
        "correct_answer": "Metformin"
    },
    "raw_text": {
        "question": "What is the first-line drug for patients with type 2 diabetes and obesity, as of 2020?\n",
        "response": "As of 2020, the first-line drug for patients with type 2 diabetes and obesity is typically **metformin**, which is widely recommended due to its efficacy, safety, and cost-effectiveness. However, for patients with type 2 diabetes and obesity, **GLP-1 receptor agonists** (e.g., liraglutide, semaglutide) or **SGLT2 inhibitors** (e.g., empagliflozin, dapagliflozin) are increasingly considered as first-line options, especially if there is a need for weight loss or cardiovascular risk reduction. These medications have shown benefits in glycemic control, weight management, and cardiovascular outcomes.\n\nThe choice of therapy should be individualized based on patient characteristics, comorbidities, and preferences, as outlined in guidelines from organizations like the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)."
    },
    "nodes": [
        {
            "id": "ctx0",
            "annotation": false,
            "start": 0,
            "end": 87,
            "label": "context",
            "text": "What is the first-line drug for patients with type 2 diabetes and obesity, as of 2020?\n",
            "source": "question"
        },
        {
            "id": "resp0",
            "annotation": false,
            "start": 0,
            "end": 106,
            "label": "fact",
            "text": "As of 2020, the first-line drug for patients with type 2 diabetes and obesity is typically **metformin**, ",
            "source": "response"
        },
        {
            "id": "resp1",
            "annotation": false,
            "start": 106,
            "end": 187,
            "label": "fact",
            "text": "which is widely recommended due to its efficacy, safety, and cost-effectiveness. ",
            "source": "response"
        },
        {
            "id": "resp2",
            "annotation": false,
            "start": 187,
            "end": 416,
            "label": "fact",
            "text": "However, for patients with type 2 diabetes and obesity, **GLP-1 receptor agonists** (e.g., liraglutide, semaglutide) or **SGLT2 inhibitors** (e.g., empagliflozin, dapagliflozin) are increasingly considered as first-line options, ",
            "source": "response"
        },
        {
            "id": "resp3",
            "annotation": false,
            "start": 416,
            "end": 496,
            "label": "reasoning",
            "text": "especially if there is a need for weight loss or cardiovascular risk reduction. ",
            "source": "response"
        },
        {
            "id": "resp4",
            "annotation": false,
            "start": 496,
            "end": 604,
            "label": "fact",
            "text": "These medications have shown benefits in glycemic control, weight management, and cardiovascular outcomes.\n\n",
            "source": "response"
        },
        {
            "id": "resp5",
            "annotation": false,
            "start": 604,
            "end": 717,
            "label": "reasoning",
            "text": "The choice of therapy should be individualized based on patient characteristics, comorbidities, and preferences, ",
            "source": "response"
        },
        {
            "id": "resp6",
            "annotation": false,
            "start": 717,
            "end": 869,
            "label": "fact",
            "text": "as outlined in guidelines from organizations like the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).",
            "source": "response"
        }
    ],
    "edges": [
        {
            "id": "e0",
            "from_node_id": "ctx0",
            "to_node_id": "resp0",
            "label": "reason:fact-detail"
        },
        {
            "id": "e1",
            "from_node_id": "resp0",
            "to_node_id": "resp1",
            "label": "reason:fact-detail"
        },
        {
            "id": "e2",
            "from_node_id": "resp0",
            "to_node_id": "resp2",
            "label": "reason:fact-detail"
        },
        {
            "id": "e3",
            "from_node_id": "resp1",
            "to_node_id": "resp2",
            "label": "reason:fact-detail"
        },
        {
            "id": "e4",
            "from_node_id": "resp0",
            "to_node_id": "resp3",
            "label": "reason:fact-detail"
        },
        {
            "id": "e5",
            "from_node_id": "resp1",
            "to_node_id": "resp3",
            "label": "reason:fact-detail"
        },
        {
            "id": "e6",
            "from_node_id": "resp2",
            "to_node_id": "resp3",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e7",
            "from_node_id": "resp2",
            "to_node_id": "resp4",
            "label": "reason:fact-detail"
        },
        {
            "id": "e8",
            "from_node_id": "resp3",
            "to_node_id": "resp4",
            "label": "reason:concept-example"
        },
        {
            "id": "e9",
            "from_node_id": "resp3",
            "to_node_id": "resp5",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e10",
            "from_node_id": "resp4",
            "to_node_id": "resp5",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e11",
            "from_node_id": "resp5",
            "to_node_id": "resp6",
            "label": "reason:fact-detail"
        }
    ]
}